Lennox-Gastaut syndrome treatment market to grow at a CAGR of 4.42%: Cedars-Sinai Health System and Cision Ltd among key vendors - Technavio

NEW YORK, April 12, 2023 /PRNewswire/ -- The Lennox-Gastaut syndrome treatment market size is forecasted to increase by USD 684.75 million from 2021 to 2026, at a CAGR of 4.42%, according to the recent market study by Technavio. The growth of the market will be driven by the rising population with risk factors for LGS (Lennox-Gastaut Syndrome), growing awareness of LGS, and orphan drug designation. Charts & data tables about market size and forecast period (2022-2026) have been covered in this report. Download the sample report

Vendor analysis: Vendor offerings -

Technavio has extensively analyzed 15 major vendors, including Akron Children's Hospital, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Cedars-Sinai Health System, Cision Ltd, Eisai Co. Ltd., Epilepsy Foundation, GlaxoSmithKline Plc, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, Upsher Smith Laboratories LLC, Viatris Inc., and Johnson and Johnson. The key offerings of some of these vendors are listed below:

• Cedars-Sinai Health System - The company offers Lennox-Gastaut syndrome treatment that includes corpus callosotomy, which is used to treat atonic seizures.
• Cision Ltd - The company offers Lennox-Gastaut syndrome treatment that includes Onfi tablets, which are used to treat seizures.
• Eisai Co. Ltd. - The company offers Lennox-Gastaut syndrome treatment that includes valproate valproic acid, which is used against a wide spectrum of seizures.
• Epilepsy Foundation - The company offers Lennox-Gastaut syndrome treatment, which is used to prevent seizures.
• GlaxoSmithKline Plc - The company offers Lennox-Gastaut syndrome treatment that includes rotavirus vaccine, which is used to prevent rotavirus gastroenteritis.

Key benefits for industry players & stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report.

Market segmentation:

The market is segmented by type (non-surgical treatment and surgical treatment) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

The non-surgical segment will account for a significant share of the market growth during the forecast period. Medications and ketogenic food are the non-surgical treatment plans recommended to mitigate the effects of LGS. Valproate, topiramate, and lamotrigine are some of the medications considered first-line therapies for the treatment of LGS. The adoption of such treatment options is expected to drive the growth of the non-surgical treatment segment during the forecast period. Recent drug approvals for the treatment of LGS will also augment market growth.

Europe will account for 36% of the market's growth during the forecast period. Germany and UK are the key countries for the Lennox-Gastaut Syndrome treatment market in the region. Moreover, market growth in this region will be faster than the growth of the market in other regions. North America will also be a key contributor to global market growth. Awareness about LGS is increasing across this region, especially in the US and Canada. Funding for research on LGS is also increasing in the region. These factors will support the growth of the market in North America during the forecast period.

Get a holistic overview of the market segments by industry experts to evaluate and develop growth strategies. Download the sample

Market dynamics:

Key drivers:

• Rising population with risk factors for LGS
• Growing awareness of LGS
• Orphan drug designation

Cortical dysplasia, stroke, trauma, perinatal hypoxia, and tuberous sclerosis are the main risk factors for LGS. In addition, the number of patients with these medical conditions is increasing. Other risk factors include congenital infections and central nervous system infections, such as encephalitis and meningitis. The growing prevalence of these infectious diseases increases the risk of the development of LGS. As per the CDC data in 2018, approximately one out of every 200 babies was born with congenital cytomegalovirus (CMV) infection in the US. Hence, a rise in the number of patients with these risk factors is expected to increase the prevalence of LGS, thereby driving the growth of the global LGS treatment market during the forecast period.

Major Trends:

• Introduction of phytochemicals
• Advances in surgical treatments
• Strategic alliances

Phytochemicals are biologically active compounds produced from plants. Phytochemical-based treatments have fewer side effects than chemical drugs. Therefore, some pharmaceutical companies have introduced plant-derived cannabinoid therapeutics for the treatment of patients with LGS, especially among those who are resistant to currently available treatments. For instance, in June 2018, GW Pharmaceuticals plc announced that the US FDA approved its EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with LGS in patients aged two years and above. Therefore, the introduction of phytochemicals will support market growth during the forecast period.

Key challenges:

• Difficulty in diagnosing LGS
• Side effects associated with available treatment
• Increasing popularity of generics

The effective treatment of LGS requires an accurate and early diagnosis. This is because the characteristics of LGS-related seizures and the features of electroencephalogram (EEG) are not pathognomonic. Moreover, to identify tonic seizures during sleep, along with the recording of surface electromyography, video recording, and EEG recording are required. Seizure types and EEG features of LGS, which are not static but evolve and alter over time, can also make diagnosing the disease difficult. Therefore, the lack of confirmatory diagnosis and other issues associated with the currently available diagnostics are expected to limit the growth of the global LGS treatment market during the forecast period.

To get detailed insights about market drivers, challenges, and trends, buy the report

What are the key data covered in this Lennox-Gastaut syndrome treatment market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the Lennox-Gastaut syndrome treatment market between 2022 and 2026
• Precise estimation of the size of the Lennox-Gastaut syndrome treatment market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the Lennox-Gastaut syndrome treatment market industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of Lennox-Gastaut syndrome treatment market vendors

Related Reports:

The global Dravet syndrome treatment market size is estimated to grow by USD 575.14 million between 2022 and 2027, accelerating at a CAGR of 9.6%. This report extensively covers market segmentation by product (SDGs, TGDs, and FGDs), distribution channel (hospital pharmacy, retail pharmacy, e-commerce, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).

The chronic fatigue syndrome therapeutics market size is expected to increase by USD 51.84 million by 2026, and the market's growth momentum will progress at a CAGR of 4.31%. This market research report extensively covers market segmentation by product (pain relievers and NSAIDs, antidepressant and antipsychotic drugs, and antimicrobial and immunomodulatory drugs) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

Browse for Technavio Health Care market reports

Table of contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments 
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type 
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 Non-surgical treatment - Market size and forecast 2021-2026 
• Exhibit 28: Chart on Non-surgical treatment - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Non-surgical treatment - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Non-surgical treatment - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Non-surgical treatment - Year-over-year growth 2021-2026 (%)

• 5.4 Surgical treatment - Market size and forecast 2021-2026
• Exhibit 32: Chart on Surgical treatment - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Surgical treatment - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Surgical treatment - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Surgical treatment - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type 
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 Canada - Market size and forecast 2021-2026
• Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 China - Market size and forecast 2021-2026
• Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 Cedars-Sinai Health System 
• Exhibit 85: Cedars-Sinai Health System - Overview
• Exhibit 86: Cedars-Sinai Health System - Business segments
• Exhibit 87: Cedars-Sinai Health System - Key offerings
• Exhibit 88: Cedars-Sinai Health System - Segment focus

• 10.4 Cision Ltd 
• Exhibit 89: Cision Ltd - Overview
• Exhibit 90: Cision Ltd - Product / Service
• Exhibit 91: Cision Ltd - Key offerings

• 10.5 Eisai Co. Ltd. 
• Exhibit 92: Eisai Co. Ltd. - Overview
• Exhibit 93: Eisai Co. Ltd. - Business segments
• Exhibit 94: Eisai Co. Ltd. - Key offerings
• Exhibit 95: Eisai Co. Ltd. - Segment focus

• 10.6 Epilepsy Foundation 
• Exhibit 96: Epilepsy Foundation - Overview
• Exhibit 97: Epilepsy Foundation - Product / Service
• Exhibit 98: Epilepsy Foundation - Key offerings

• 10.7 GlaxoSmithKline Plc 
• Exhibit 99: GlaxoSmithKline Plc - Overview
• Exhibit 100: GlaxoSmithKline Plc - Business segments
• Exhibit 101: GlaxoSmithKline Plc - Key news
• Exhibit 102: GlaxoSmithKline Plc - Key offerings
• Exhibit 103: GlaxoSmithKline Plc - Segment focus

• 10.8 Johnson and Johnson 
• Exhibit 104: Johnson and Johnson - Overview
• Exhibit 105: Johnson and Johnson - Business segments
• Exhibit 106: Johnson and Johnson - Key news
• Exhibit 107: Johnson and Johnson - Key offerings
• Exhibit 108: Johnson and Johnson - Segment focus

• 10.9 Supernus Pharmaceuticals Inc. 
• Exhibit 109: Supernus Pharmaceuticals Inc. - Overview
• Exhibit 110: Supernus Pharmaceuticals Inc. - Product / Service
• Exhibit 111: Supernus Pharmaceuticals Inc. - Key offerings

• 10.10 Teva Pharmaceutical Industries Ltd. 
• Exhibit 112: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 113: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 116: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.11 UCB SA 
• Exhibit 117: UCB SA - Overview
• Exhibit 118: UCB SA - Product / Service
• Exhibit 119: UCB SA - Key offerings

• 10.12 Upsher Smith Laboratories LLC 
• Exhibit 120: Upsher Smith Laboratories LLC - Overview
• Exhibit 121: Upsher Smith Laboratories LLC - Product / Service
• Exhibit 122: Upsher Smith Laboratories LLC - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 123: Inclusions checklist
• Exhibit 124: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 125: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 126: Research methodology
• Exhibit 127: Validation techniques employed for market sizing
• Exhibit 128: Information sources

• 11.5 List of abbreviations 
• Exhibit 129: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio